BR0201366A - Vìrus da raiva mutante recombinante, mutante, vìrus da raiva recombinante, e, vacina anti-raiva viva atenuada - Google Patents

Vìrus da raiva mutante recombinante, mutante, vìrus da raiva recombinante, e, vacina anti-raiva viva atenuada

Info

Publication number
BR0201366A
BR0201366A BR0201366-5A BR0201366A BR0201366A BR 0201366 A BR0201366 A BR 0201366A BR 0201366 A BR0201366 A BR 0201366A BR 0201366 A BR0201366 A BR 0201366A
Authority
BR
Brazil
Prior art keywords
arg
recombinant
mutant
rabies
virus
Prior art date
Application number
BR0201366-5A
Other languages
English (en)
Inventor
Teshome Mebatsion
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR0201366A publication Critical patent/BR0201366A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"VìRUS DA RAIVA MUTANTE RECOMBINANTE, MUTANTE, VìRUS DA RAIVA RECOMBINANTE, E, VACINA ANTI-RAIVA VIVA ATENUADA". A presente invenção descreve mutantes de RV recombinantes compreendendo uma mutação combinada em duas partes diferentes do genoma viral, envolvendo os genes P e G. As mutações no gene P preferivelmente englobam resíduos 139 a 170, mais preferivelmente resíduos 139 a 149, mais preferivelmente resíduos 143-149. A mutação pode ser uma substituição ou deleção de um ou mais aminoácidos na região acima, assim como combinações de deleção e substituição. Os mutantes preferidos de acordo com a invenção podem ser obtidos por deleção de resíduos 143 a 149 ou 139 a 149 de fosfoproteína (P) de vírus da raiva e simultaneamente substituindo Arg na posição 333 de glicoproteína em outro resíduo, preferivelmente Asp em vez de Arg. De modo surpreendente, quando estas mutações foram introduzidas em vírus da raiva faltando Arg em posição 333 de sua proteína G, uma redução dramática na patogenicidade para camundongos lactentes foi observada. Esta verificação inesperada teve uma vantagem profunda no desenvolvimento de vacinas contra raiva vivas atenuadas mais seguras. A mutação no gene G pode compreender uma mutação do códon Arg~ 333~ em um códon que difere por um, dois ou três nucleotídeos do referido códon Arg~ 333~. Preferivelmente, os mutantes são mutantes de uma cepa RV em que todos os três nucleotídeos de códon Arg~ 333~ são substituídos.
BR0201366-5A 2001-04-23 2002-04-22 Vìrus da raiva mutante recombinante, mutante, vìrus da raiva recombinante, e, vacina anti-raiva viva atenuada BR0201366A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01201464 2001-04-23
EP01203773 2001-10-05

Publications (1)

Publication Number Publication Date
BR0201366A true BR0201366A (pt) 2003-06-10

Family

ID=26076884

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0201366-5A BR0201366A (pt) 2001-04-23 2002-04-22 Vìrus da raiva mutante recombinante, mutante, vìrus da raiva recombinante, e, vacina anti-raiva viva atenuada

Country Status (10)

Country Link
US (1) US6887479B2 (pt)
EP (1) EP1253197B1 (pt)
AR (1) AR033873A1 (pt)
AT (1) ATE316572T1 (pt)
BR (1) BR0201366A (pt)
CA (1) CA2382993A1 (pt)
DE (1) DE60208854T2 (pt)
ES (1) ES2257505T3 (pt)
PT (1) PT1253197E (pt)
TR (1) TR200201081A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2573631A1 (en) * 2004-07-12 2006-02-16 Thomas Jefferson University Recombinant rabies virus compositions
BRPI0617373B1 (pt) 2005-10-14 2022-04-05 The Goverment of The United States of America, Representado por, The Secretary of The Department of Health and Human Services, Centers for Disease Control and Prevention Composições e métodos do vírus da raiva
CN104059890A (zh) * 2005-12-14 2014-09-24 乔治亚大学研究基金公司 狂犬病疫苗
FR2944292B1 (fr) 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
RU2013102929A (ru) 2010-06-24 2014-07-27 Зе Гавермент Оф Зе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Зе Секретари Оф Зе Департмент Оф Хэлс Энд Хьюман Сервисез, Сентерз Фо Дизиз Контрол Энд Привеншн Пан-лиссавирусные вакцины против бешенства
DK2670843T3 (en) 2011-02-03 2015-01-05 Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services MULTIVALENT VACCINES FOR RABIES VIRUS AND FILOVIRUS
US11041170B2 (en) 2016-04-04 2021-06-22 Thomas Jefferson University Multivalent vaccines for rabies virus and coronaviruses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352231C (en) * 1998-11-27 2010-06-01 Akzo Nobel N.V. Stable, attenuated rabies virus mutants and live vaccines thereof

Also Published As

Publication number Publication date
TR200201081A3 (tr) 2002-11-21
DE60208854T2 (de) 2006-08-17
ES2257505T3 (es) 2006-08-01
TR200201081A2 (tr) 2002-11-21
US20020164356A1 (en) 2002-11-07
US6887479B2 (en) 2005-05-03
CA2382993A1 (en) 2002-10-23
DE60208854D1 (de) 2006-04-13
EP1253197A1 (en) 2002-10-30
ATE316572T1 (de) 2006-02-15
PT1253197E (pt) 2006-06-30
AR033873A1 (es) 2004-01-07
EP1253197B1 (en) 2006-01-25

Similar Documents

Publication Publication Date Title
US8435535B2 (en) Fusion proteins of HIV regulatory/accessory proteins
JP2005533855A (ja) 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
JP2009544333A5 (pt)
BR0312173A (pt) Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante
CA2334857A1 (en) Interferon inducing genetically engineered attenuated viruses
RU2012107671A (ru) Композиция для лечения инфекции вирусом гепатита в
BRPI0504945A8 (pt) Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
BR0201366A (pt) Vìrus da raiva mutante recombinante, mutante, vìrus da raiva recombinante, e, vacina anti-raiva viva atenuada
CN106831960B (zh) 一种人乳头瘤病毒6型l1蛋白的突变体
JP2020509770A5 (pt)
WO2002072802A3 (en) Live attenuated strains of prrs virus
AR126396A1 (es) VARIANTES DESOPTIMIZADAS DE SARS-CoV-2 Y MÉTODOS Y USOS DE LAS MISMAS
JP6863966B2 (ja) 標的ポリペプチドを提示するためのポリペプチド担体及びその使用
JPWO2021154828A5 (pt)
JP7224332B2 (ja) ヒトパピローマウイルス１６型のｌ１タンパク質の変異体
US11154607B2 (en) Genetically attenuated nucleic acid vaccine
BR9915703A (pt) Mutante do vìrus da raiva recombinante, e, vacina anti-rábica atenuada viva
WO2023064993A1 (en) Chimeric betacoronavirus spike polypeptides
AR031599A1 (es) Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz
JP2021535077A (ja) ヒトパピローマウイルス１８型のｌ１タンパク質の変異体
BR112020024687A2 (pt) Mutante de proteína l1 tipo 66 de papilomavírus humano
US20130209513A1 (en) Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
CA2351010A1 (en) A broad spectrum infectious bursal disease virus vaccine
KR20220132454A (ko) 약독화된 레오바이러스 기반의 백신 조성물 및 이의 용도
JP2024518565A (ja) 組換え重複ペプチド及びネイティブタンパク質を含むワクチン製剤

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements